This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Basil M. Rifkind, MD, FRCP; Beth Schucker, MS; David J. Gordon, MD, PhD

JAMA. 1999;281:180-181.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Familial hypercholesterolemia (FH) is one of the more common genetic diseases, affecting about 1 in 500 persons in its heterozygous form (HeFH) and about 1 per 1 million persons in its most severe homozygous form.¹ This disease, in which high levels of low-density lipoprotein cholesterol (LDL-C) are associated with early and often severe manifestations of coronary heart disease (CHD), even in the absence of other risk factors, has served as a paradigm for the atherogenicity of elevated LDL-C levels. The study of this disorder has provided one of the scientific foundations for the National Cholesterol Education Program (NCEP)^2-3 approach that makes LDL-C the primary target of cholesterol-lowering treatment for the prevention of CHD. It is therefore ironic that HeFH, the most common form of the disease, is often neglected or undertreated in adults and children. This is . . . [Full Text of this Article]

Author Affiliations: Division of Heart and Vascular Diseases, National Heart, Lung, and Blood Institute, Bethesda, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia: A Randomized Controlled Trial
Evan A. Stein, D. Roger Illingworth, Peter O. Kwiterovich, Jr, Chris A. Liacouras, Martti A. Siimes, Marc S. Jacobson, Thomas G. Brewster, Paul Hopkins, Michael Davidson, Kevin Graham, Frederick Arensman, Robert H. Knopp, Carlos DuJovne, Christine L. Williams, Jonathan L. Isaacsohn, Carol A. Jacobsen, Peter M. Laskarzewski, Sharon Ames, and Glenn J. Gormley
JAMA. 1999;281(2):137-144.
ABSTRACT | FULL TEXT  

What you should know about cholesterol
JAMA. 1999;281(2):206.
PDF  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Beneficial Impact of Xuezhikang on Cardiovascular Events and Mortality in Elderly Hypertensive Patients With Previous Myocardial Infarction From the China Coronary Secondary Prevention Study (CCSPS)
Li et al.
J Clin Pharmacol 2009;49:947-956.
ABSTRACT | FULL TEXT  

Under-treated high-risk patients: identifying patients in high-risk subgroups and treating them to LDL-C targets
Schuster
Eur Heart J Suppl 2005;7:A20-A28.
ABSTRACT | FULL TEXT  

Detection of subclinical atherosclerosis by electron beam tomography in females with heterozygous familial hypercholesterolaemia
Santos et al.
Heart 2004;90:92-94.
FULL TEXT  

Parental attitude towards genetic testing for familial hypercholesterolaemia in children
Umans-Eckenhausen et al.
J. Med. Genet. 2002;39:e49-49.
FULL TEXT  

An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines
Ansell et al.
JAMA 1999;282:2051-2057.
ABSTRACT | FULL TEXT